NCT00119210

Pilot Study of Bupropion for Smoking Cessation in Postpartum Non-breastfeeding Women

Bupropion for Smoking Cessation in Postpartum Women

• Status: Terminated
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: Massachusetts General Hospital · Academic / Other
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this small preliminary study is to determine whether it is feasible to recruit women smokers who have just delivered a baby and are not breastfeeding into a study that would test whether starting bupropion, a smoking cessation medication, after a baby's birth helps a postpartum woman to stop smoking.

Detailed description

Purpose: A pilot randomized double-blind placebo-controlled trial is testing the feasibility of conducting a full-scale trial of the efficacy of bupropion SR vs. placebo in non-breastfeeding postpartum women who smoked \>1 cigarette in the last month of pregnancy and want to stop smoking. The study will estimate achievable enrollment and retention rates; estimate the effect size of the drug on tobacco abstinence; assess the tolerability of bupropion in postpartum women; and allow refinement of recruitment, retention, intervention, and assessment protocols. Research Design: Pilot double-blind placebo-controlled randomized clinical trial. Study Population: 40 postpartum women aged 18 years or older who smoked \> 1 cigarette in the last month of pregnancy, want to stop smoking, and are not breastfeeding. Subjects will be recruited postpartum while hospitalized after delivery. Intervention: Bupropion SR (or matching placebo) for 8 weeks, starting immediately post-delivery. The dose is 150 mg qd for one week then 150 mg bid for 7 weeks. All subjects will receive behavioral counseling delivered face-to-face during the post-delivery hospitalization and by telephone 4 times over 8 weeks. Outcome Measures: (assessed at 2, 4, 8, and 12 weeks postpartum): 1. Study eligibility, recruitment, and retention rates (primary outcome). 2. Tobacco abstinence (7-day point prevalence nonsmoking by self-report and confirmed by saliva cotinine at 2 weeks, 8 weeks (end of drug treatment), and 12 weeks postpartum. 3. Postpartum weight loss and symptoms of depression and anxiety. 4. Tolerability of postpartum bupropion, assessed by medication adherence and adverse effects.

Conditions

• Tobacco Use Disorder

Interventions

Type	Name	Description
DRUG	Bupropion SR
OTHER	placebo

Timeline

• Start date: 2005-03-01
• Completion: 2006-03-01
• First posted: 2005-07-13
• Last updated: 2011-04-29

Locations

1 site across 1 country: United States